Search
Find a recruiting study
7,106 recruiting studies with US sites, from the official ClinicalTrials.gov registry (refreshed Nov 1, 2026). No sign-up needed.
Most recently updated studies · page 101 of 297
- RecruitingPhase 1
Study of BHV-1300 in Graves' Disease
Biohaven Therapeutics Ltd.
- Location
- South Gate, CA + 9 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Artiva Biotherapeutics, Inc.
- Location
- Tuscaloosa, AL + 29 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Mahzi Therapeutics
- Location
- Oakland, CA + 2 other US sites
- Eligibility basics
- Ages 2–25
- Recruiting
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
Sanmai Technologies PBC dba Sanmai
- Location
- Tucson, AZ + 3 other US sites
- Eligibility basics
- Ages 22–80
- RecruitingPhase 1
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
Terrestrial Bio, Inc.
- Location
- Tempe, AZ
- Eligibility basics
- Ages 18–60
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- La Jolla, CA + 30 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Alexion Pharmaceuticals, Inc.
- Location
- Aurora, CO
- Eligibility basics
- Ages 2–18
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Huntsville, AL + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Viatris Innovation GmbH
- Location
- Doral, FL + 13 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Novartis Pharmaceuticals
- Location
- Garden Grove, CA + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
Novartis Pharmaceuticals
- Location
- Foley, AL + 26 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens
Gilead Sciences
- Location
- Berkeley, MI + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
- Location
- Los Angeles, CA + 9 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Implicit Bioscience
- Location
- Seattle, WA + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
Healx Limited
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 8 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
Novartis Pharmaceuticals
- Location
- Bentonville, AR + 6 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 4
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Bausch Health Americas, Inc.
- Location
- Bryant, AR + 13 other US sites
- Eligibility basics
- Ages 9–11
- RecruitingPhase 4
Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis
Eidos Therapeutics, a BridgeBio company
- Location
- St Louis, MO
- Eligibility basics
- Ages 18–80
- RecruitingPhase 1/Phase 2
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
Ipsen
- Location
- Downey, CA + 3 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Encino, CA + 35 other US sites
- Eligibility basics
- Ages 18–55
- Recruiting
External Therapy for Tinnitus Management
Restorear Devices LLC
- Location
- Bozeman, MT
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
GlaxoSmithKline
- Location
- Newport Beach, CA + 37 other US sites
- Eligibility basics
- Ages 40–75
- RecruitingPhase 2
Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
- Location
- Phoenix, AZ + 21 other US sites
- Eligibility basics
- Ages 12–55
Data source: daily sync of the ClinicalTrials.gov API. How we list studies